Company Filing History:
Years Active: 2012-2015
Title: Thorsten Meyer: Innovations in Anthelmintic Agents and Enantioselective Synthesis
Introduction:
Thorsten Meyer, a renowned inventor hailing from Schwabenheim, Germany, has made significant contributions to the field of pharmaceuticals and chemical synthesis. With five patents to his name, Meyer has demonstrated an exceptional ability to develop novel compounds and processes that have the potential to revolutionize the pharmaceutical industry.
Latest Patents:
Meyer's most recent patents showcase his expertise in the development of anthelmintic agents and enantioselective synthesis. His invention of "Anthelmintic Agents and Their Use" focuses on compounds and salts that possess anthelmintic properties, making them valuable for treating infestations caused by parasitic worms. These compounds, along with their manufacturing processes, pharmaceutical compositions, and treatment applications, have tremendous potential in animal healthcare.
In addition, Meyer's patent for the "Enantioselective Synthesis of 6-Amino-7-Hydroxy-4,5,6,7-Tetrahydro-Imidazo[4,5,1-jk][1]-Benzazepin-2[1H]-one and Zilpaterol" demonstrates his skill in developing a unique process for the hydrogenation of ketooximes. This invention specifically targets the formation of the aminoalcohol stereoisomer, which has implications for the synthesis of zilpaterol, a compound utilized in animal treatment and medicaments.
Career Highlights:
Thorsten Meyer has earned a commendable reputation during his career, leveraging his expertise in the pharmaceutical and chemical industries. Working with Intervet International B.V., a leading veterinary pharmaceutical company, he has showcased his ability to provide innovative solutions to complex challenges in the field. Meyer's contributions to the development of effective anthelmintic agents and enantioselective synthesis methods have undoubtedly elevated the capabilities of the company.
Collaborations:
Throughout his career, Meyer has had the opportunity to collaborate with esteemed colleagues who share his passion for innovation. Notably, he has worked alongside Christophe Pierre Alain Chassaing and Jörg Schröder, who have also made significant contributions in the field of pharmaceutical research and development. These collaborations have likely fostered an environment conducive to sharing knowledge and pushing the boundaries of scientific advancements.
Conclusion:
Thorsten Meyer's patents in anthelmintic agents and enantioselective synthesis testify to his extraordinary skills and deep understanding of the pharmaceutical industry. His groundbreaking research and inventions have the potential to improve the lives of both humans and animals, addressing critical health concerns and enriching the field of veterinary medicine. As he continues to push the boundaries of innovation, we eagerly await Meyer's future contributions and their impact on the world of pharmaceuticals.